DE602004023476D1 - Dimerisiertes peptid - Google Patents

Dimerisiertes peptid

Info

Publication number
DE602004023476D1
DE602004023476D1 DE602004023476T DE602004023476T DE602004023476D1 DE 602004023476 D1 DE602004023476 D1 DE 602004023476D1 DE 602004023476 T DE602004023476 T DE 602004023476T DE 602004023476 T DE602004023476 T DE 602004023476T DE 602004023476 D1 DE602004023476 D1 DE 602004023476D1
Authority
DE
Germany
Prior art keywords
peptide
tumor antigen
dimerized peptide
antigen peptide
dimerized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004023476T
Other languages
English (en)
Inventor
Hideo Takasu
Fumio Samizo
Haruo Sugiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
International Institute of Cancer Immunology Inc
Sumitomo Pharma Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Sumitomo Dainippon Pharma Co Ltd
International Institute of Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Sumitomo Dainippon Pharma Co Ltd, International Institute of Cancer Immunology Inc filed Critical Chugai Pharmaceutical Co Ltd
Publication of DE602004023476D1 publication Critical patent/DE602004023476D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
DE602004023476T 2003-01-15 2004-01-15 Dimerisiertes peptid Expired - Lifetime DE602004023476D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003007122 2003-01-15
PCT/JP2004/000254 WO2004063217A1 (ja) 2003-01-15 2004-01-15 二量体化ペプチド

Publications (1)

Publication Number Publication Date
DE602004023476D1 true DE602004023476D1 (de) 2009-11-19

Family

ID=32709100

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004023476T Expired - Lifetime DE602004023476D1 (de) 2003-01-15 2004-01-15 Dimerisiertes peptid

Country Status (13)

Country Link
US (2) US20060217297A1 (de)
EP (2) EP1584627B1 (de)
JP (2) JP4498274B2 (de)
KR (2) KR20120054644A (de)
CN (2) CN101851275A (de)
AT (1) ATE444969T1 (de)
AU (1) AU2004204031B2 (de)
BR (1) BRPI0406800B8 (de)
CA (1) CA2513701C (de)
DE (1) DE602004023476D1 (de)
ES (1) ES2332590T3 (de)
HK (2) HK1081975A1 (de)
WO (1) WO2004063217A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4932199A (en) * 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US20040097703A1 (en) * 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
JP2005515157A (ja) * 2001-05-25 2005-05-26 トマス ジェファソン ユニバーシティ 多様な治療様式のための主成分としての選択的スプライスフォーム
US7342092B2 (en) * 2002-09-12 2008-03-11 International Institute Of Cancer Immunology, Inc. Cancer antigen peptide formulations
US20080070835A1 (en) 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
DK1731605T3 (da) * 2004-03-31 2010-05-25 Int Inst Cancer Immunology Inc Cancerantigenpeptider der er afledt af WT1
DK1853305T3 (en) * 2005-02-04 2014-12-01 Survac Aps Survivin-peptide vaccine
JP4394724B2 (ja) * 2005-11-30 2010-01-06 株式会社癌免疫研究所 新規ペプチド化合物
CA2886551A1 (en) 2006-02-22 2007-08-30 Haruo Sugiyama Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
ES2333374T3 (es) * 2006-02-23 2010-02-19 FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH Peptidos y derivados de peptidos, la produccion de los mismos asi como su uso para preparar una composicion farmaceutica terapeutica y/o preventivamente activa.
AU2007340679B2 (en) * 2006-12-28 2013-09-12 International Institute Of Cancer Immunology, Inc. HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising the same
PT2119778E (pt) 2007-02-27 2016-02-15 Int Inst Cancer Immunology Inc Método para ativação de célula t auxiliar e composição para utilização no método
KR20100080519A (ko) * 2007-08-30 2010-07-08 큐어디엠 인코포레이티드 프로섬 펩타이드 및 이의 유사체의 조성물 및 이의 이용 방법
AR083295A1 (es) 2010-10-05 2013-02-13 Univ Osaka Metodo para activar celulas t auxiliares
CA2819416C (en) * 2010-12-02 2019-04-30 Bionor Immuno As Peptide scaffold design
CA2822684A1 (en) * 2010-12-23 2012-06-28 Intercell Austria Ag Oprf/i agents and their use in hospitalized and other patients
US9493514B2 (en) 2011-01-06 2016-11-15 Bionor Immuno As Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes
JP6082901B2 (ja) * 2011-01-31 2017-02-22 オリンパス株式会社 ワクチン・アジュバント
WO2014007266A1 (ja) 2012-07-02 2014-01-09 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
WO2014098012A1 (ja) 2012-12-17 2014-06-26 大塚製薬株式会社 ヘルパーt細胞の活性化方法
ES2694328T3 (es) 2013-03-12 2018-12-19 Sumitomo Dainippon Pharma Co., Ltd. Composición acuosa líquida
WO2014157704A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
MY171854A (en) * 2013-03-29 2019-11-05 Sumitomo Dainippon Pharma Co Ltd Wt1 antigen peptide conjugate vaccine
US20160229894A1 (en) 2013-10-17 2016-08-11 Seoul National University R&Db Foundation Alpha helix cell-penetrating peptide multimer, preparation method therefor and use therefor
US10471136B2 (en) 2014-09-27 2019-11-12 Sumitomo Dainippon Pharma Co., Ltd. Pharmaceutical composition for injection
JP6671141B2 (ja) * 2014-10-21 2020-03-25 大日本住友製薬株式会社 懸濁液剤
WO2016186177A1 (ja) * 2015-05-20 2016-11-24 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドおよび免疫調節剤の併用
CA2992419C (en) * 2015-07-14 2023-08-15 Yeda Research And Development Co. Ltd. Peptide combinations for use in the diagnosis of schizophrenia
US20200368338A1 (en) * 2017-12-27 2020-11-26 Sumitomo Dainippon Pharma Co., Ltd. Conjugate of wt1-derived peptides and composition comprising the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0841068B1 (de) * 1995-06-01 2006-07-12 Kishimoto, Tadamitsu Wachstumsinhibitor gegen leukämische zellen, der antisense-oligonukleotidderivate gegen das wilms-tumorgen enthält
JP3060287B2 (ja) 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
MXPA01003344A (es) * 1998-09-30 2004-04-21 Corixa Corp Composiciones y metodos para inmunoterapia especifica de wt1.
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
AU2002222610A1 (en) 2000-12-13 2002-06-24 Sumitomo Pharmaceuticals Company, Limited Transgenic animal expressing hla-a24 and utilization thereof
US20040097703A1 (en) * 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US8735357B2 (en) * 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
WO2003106682A1 (ja) * 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
US20080070835A1 (en) 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
DK1731605T3 (da) 2004-03-31 2010-05-25 Int Inst Cancer Immunology Inc Cancerantigenpeptider der er afledt af WT1

Also Published As

Publication number Publication date
KR20120054644A (ko) 2012-05-30
EP1584627B1 (de) 2009-10-07
JP4926231B2 (ja) 2012-05-09
ATE444969T1 (de) 2009-10-15
AU2004204031B2 (en) 2010-03-04
HK1081975A1 (en) 2006-05-26
JPWO2004063217A1 (ja) 2006-06-01
WO2004063217A1 (ja) 2004-07-29
CA2513701C (en) 2013-06-18
EP1584627A1 (de) 2005-10-12
BRPI0406800B1 (pt) 2020-08-11
JP4498274B2 (ja) 2010-07-07
US20100292164A1 (en) 2010-11-18
CA2513701A1 (en) 2004-07-29
US20060217297A1 (en) 2006-09-28
CN1756763A (zh) 2006-04-05
BRPI0406800A8 (pt) 2016-11-01
EP2154145A3 (de) 2010-05-19
EP2154145B1 (de) 2013-04-24
EP2154145A2 (de) 2010-02-17
AU2004204031A1 (en) 2004-07-29
JP2010047603A (ja) 2010-03-04
BRPI0406800B8 (pt) 2021-05-25
CN1756763B (zh) 2010-05-26
ES2332590T3 (es) 2010-02-09
KR101399678B1 (ko) 2014-05-27
CN101851275A (zh) 2010-10-06
KR20050098863A (ko) 2005-10-12
BRPI0406800A (pt) 2006-01-17
HK1141539A1 (en) 2010-11-12
EP1584627A4 (de) 2006-03-15
US8242084B2 (en) 2012-08-14

Similar Documents

Publication Publication Date Title
ATE444969T1 (de) Dimerisiertes peptid
CY1119106T1 (el) Αντισωματα εναντι masp-2
WO2007064919A3 (en) Binding polypeptides with restricted diversity sequences
CY1117031T1 (el) Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου
WO2003102157A3 (en) Synthetic antibody phage libraries
CY1113850T1 (el) Νεα παραγωγα ινσουλινης
ATE415413T1 (de) Iap-bindende verbindungen
RS51180B (sr) Interleukin-10 antitela
DE602005008996D1 (de) Radiofluorierte peptide
WO2005012531A3 (en) Antibody cdr polypeptide sequences with restricted diversity
DK1423419T3 (da) Hybrid- og tandemekspression af Neisseria-proteiner
RS54046B1 (en) ANTI-MIOSTATIN ANTITELA
ATE497975T1 (de) Il-21-varianten
ATE542137T1 (de) Immunocytokine mit modulierter selektivität
DE60232577D1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
HK1071898A1 (en) Recombinant antibodies, and compositions and methods for making and using the same
DE502004011395D1 (de) Protein-bindende doxorubicin-peptid-derivate
PE20050962A1 (es) Anticuerpos completamente humanos contra 4-1bb humano
EP2305710A3 (de) Synthetische Antikörperphagenbibliotheken
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
ATE419861T1 (de) Peptide mit homing für lymphgefässtumor und ihre verwendung
ATE467421T1 (de) Cytokine und cytokinrezeptoren mit reduzierter immunogenität
ATE470678T1 (de) Emitter-bindende peptide, die eine veränderung der spektralen emissionseigenschaften des emitters bewirken
DE60322913D1 (de) Faserformgebende peptide, die mit selbstanordnenden peptiden interagieren
CY1117092T1 (el) Μοτιβα της οικογενειας παγκρεατικων πολυπεπτιδιων, πολυπεπτιδια και μεθοδοι που τα περιλαμβανουν

Legal Events

Date Code Title Description
8364 No opposition during term of opposition